Listing of Claims/Amendments

Please amend the claims to read as follows:

Claims 1-60 (canceled)

Claim 61 (currently amended): A compound of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein:

R^1 is H, alkyl, haloC_1-C_6 alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, $N(R^2)_2$, or NR^2aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C_1-C_6 alkyl;

R^3 is H, C_1-C_6 alkyl, Cl, F, CF_3, OCF_2H, OCF_3, OH or C_1-C_6 alkoxy;

R^4 is H, C_1-C_6 alkyl, C_1-C_6 alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, $N(R^2)_2$, or NR^2aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;

R^5 is H or C_1-C_6 alkyl;

R^6 is H or C_1-C_6 alkyl; or

R^5 and R^6 taken together with the carbon atom to form a carbonyl group;

L^1 is -$S(O_2)$-, -S(O)-, or -S-;

L^2 is -$S(O_2)$-, -S(O)-, or -S-;

X is the same or different, and is independently selected from H, halogen, CF_3, CN, OCF_2H, OCF_2CF_3, OCF_3, OR^2, C_1-C_6 alkyl, cycloalkyl, cycloalkoxy, C_1-

C_6 alkoxy, alkoxyC_1-C_6 alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, -OSO_2R^2, -$COOR^2$, -$CON(R^2)_2$, NHR^2, arylNH-, $N(R^2)_2$, or NR^2 aryl;

Y is a covalent bond, -CH_2-, -$S(O_2)$-, or  ;

Z is a covalent bond, -CH_2-, -$S(O_2)$- or  ; or

Y, R^1, Z and R^2 can be taken together with the nitrogen atom to form a heterocycloalkyl; with the proviso that if Y is a covalent bond, R^1 cannot form a N-N bond with the nitrogen atom; and

n is an integer of 0 to 4,

with the proviso that, when $R^1 = R^2 = H$ or lower alkyl, Y=Z= covalent bond, n=0 or R^3 at each occurrence is H, $L^1 = L^2 = S$ or -$S(O_2)$-, X=H, and R^4 is phenyl substituted once with –$CON(H)_2$ or –$CON(Me)_2$, then R^5 and R^6 are each independently H or C_1-C_6 alkyl.

Claim 62 (currently amended): A compound of the formula

L^1 is -SO_2-, -S- or -S(O)-;

L^2 is -SO_2-;

R^1 is H, CH_3NH-, -CH_2CF_3, -NHC_3H_7, -NHC_2H_6, -NHC_4H_9, C_1-C_6 alkyl, -CF_3, -$CH(CH_3)_2$, thiophenyl, morpholinyl, cyclopropyl, cyclopentyl, benzyl, naphthyl,
-$C(CH_3)_3$, NHphenyl, 3,5-difluorophenyl, phenyl, N-cyclopentyl or $N(CH_3)_2$;

R^2 is H or -CH_3;

R^4 is C_1-C_6 alkoxyl, cyclohexyl, cyclopentyl, phenyl, tolyl, C_3H_7, trifluoromethoxyphenyl, or -CH_3; and

each R^4 may be optionally substituted with one to three substituents, which are the same or different and are independently selected from X;

R^5 and R^6 are independently H or -CH_3;

X is H, C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, $-CF_3$, $-OCH_3$, $-OCF_3$, $-OCF_2H$, $-CH_3$ or C_1-C_6 cycloalkyl;

Y is $-SO_2-$ or  ;

Z is a covalent bond; or

R^1, Y, R^2 and Z taken together with the nitrogen atom form a morpholinyl group.

Claim 63 (previously presented): The compound according to claim 62 wherein

L^1 is $-SO_2-$ or $-CH_2-$;

L^2 is $-SO_2-$;

R^1 is $-CH_3$ or $-CF_3$; and

R^4 is phenyl, optionally substituted with one to three substituents which are the same or different, and are independently selected from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, OH, $-CF_3$ and halogen.

Claim 64 (previously presented): The compound according to claim 63 wherein R^4 is phenyl substituted with $-OCH_3$ or halogen.

Claim 65 (previously presented): The compound according to claim 64 wherein the halogen is selected from fluorine and chlorine.

Claim 66 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X and R^4 are as shown in the table below:

	X	R^4
A	$-OCH_3$	
B	$-OCH_3$	
C	$-OCF_2H$	
F	$-OCH_3$	
G	$-CH_3$	
I	$-OCH_3$	
J	$-OCF_3$	

	X	R^4
L	Cl	
O	Cl	
Q	CH_3	
Z	$-OCH_3$	
AA	$-OCH_3$	C_3H_7
AB	$-CF_3$	
AC	$-CF_3$	
AF	$-CF_3$	
AI	$-CF_3$	
AK	Cl	
AQ	Cl	

	X	R^4
AU	Cl	
AX	Cl	C_3H_7
BA	$-OCF_3$	
BB	$-OCF_3$	
BC	$-OCF_3$	
BG	$-OCH_3$	
CB	$-CH_3$	
CE	Cl	
CW	OH	
CX	OH	

	X	R^4
DA	$-OCF_2H$	
FR	H	
FS	H	
FT	H	
FW	H	

Claim 67 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X and R^4 are as shown in the table below:

	X	R^4
R	$-CF_3$	
S	Cl	
W	Cl	
AE	$-CF_3$	
AG	$-CF_3$	
AH	$-CF_3$	
AR	Cl	
AS	Cl	
BD	$-OCF_3$	

BJ	$-OCH_3$	
BZ	$-CH_3$	
CA	$-CH_3$	
FY	H	
FZ	H	
GI	Cl	
GJ	$-OCH_3$	
GL	OH	
GM	$OCH(CH_3)_2$	
GN		

Claim 68 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X, R^1 and R^4 are as shown in the table below:

	X	R^1	R^4
A	$-OCH_3$	$-CH_3$	
C	$-OCF_2H$	$-CH_3$	
G	$-CH_3$	$-CH_3$	
L	Cl	$-CH_3$	
R	$-CF_3$	$-CF_3$	

	X	R^1	R^4
S	Cl	$-CF_3$	
AB	$-CF_3$	$-CH_3$	
AT	Cl	$-N(CH_3)_2$	
BA	$-OCF_3$	$-CH_3$	
BD	$-OCF_3$	$-CF_3$	
BZ	$-CH_3$	$-CF_3$	
FS	H	$-CH_3$	
FY	H	$-CF_3$	
XXX		$-CF_3$	
XXXII	-CN	$-CF_3$	
XXXIII	$-NH_2$	$-CF_3$	

	X	R^1	R^4
XXXIV		$-CF_3$	
XXXIX	$-CONH_2$	$-CF_3$	
XXXX	$-OCH_3$	$-CF_3$	
XXXXI	-OH	$-CF_3$	
XXXII		$-CF_3$	
XXXIII		$-CF_3$	
XXXIV		$-CF_3$	
XXXXV		$-CF_3$	

Claim 69 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCH_3$ and R^1 is $-CH_3$.

Claim 70 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_2H$ and R^1 is $-CH_3$.

Claim 71 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CH_3$ and R^1 is $-CH_3$.

Claim 72 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-CH_3$.

Claim 73 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CF_3$ and R^1 is $-CF_3$.

Claim 74 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-CF_3$.

Claim 75 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CF_3$ and R^1 is $-CH_3$.

Claim 76 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-N(CH_3)_2$.

Claim 77 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_3$ and R^1 is $-CH_3$.

Claim 78 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_3$ and R^1 is $-CF_3$.

Claim 79 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CH_3$ and R^1 is $-CF_3$.

Claim 80 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-CH_3$.

Claim 81 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-CF_3$.

Claim 82 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is $-CF_3$.

Claim 83 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CH_3.

Claim 84 (previously presented): A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 61 and a pharmaceutically acceptable carrier.

Claim 85 (previously presented): A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 67 and a pharmaceutically acceptable carrier.

Claim 86 (canceled):

Claim 87 (withdrawn – currently amended): A method of treating ~~cancer, inflammatory diseases~~ inflammation, an immunomodulatory disease, or a respiratory disease ~~an immunomodulatory diseases, or a respiratory diseases~~ comprising administering to a mammal in need of such treatment an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, according to claim 61.

Claim 88 (withdrawn – currently amended): A method of treating cutaneous T cell lymphoma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, sepsis, shock, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing alveolitis, psoriasis, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn's disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease ~~(COPD)~~, bronchitis, colitis, coronary artery disease, melanoma, transplant rejection, graft versus host disease, Hashimoto's thyroiditis, Graves disease, myasthenia gravis or Goodpasture's syndrome comprising administering to a mammal in need of such treatment an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, according to claim 61.

Claim 89 (canceled):

Claim 90 (currently amended): A pharmaceutical composition made by combining ~~the~~ a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, of Claim 61 and a pharmaceutically acceptable carrier therefor.

Claim 91 (withdrawn – currently amended): A process for making a pharmaceutical composition comprising combining a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, of Claim 61 and a pharmaceutically acceptable carrier.

Claim 92 (withdrawn – currently amended): A method of treating rheumatoid arthritis which comprises co-administration of or use in combination with a compound selected from the class consisting of a COX-2 inhibitor, a

COX-1 inhibitor, an immunosuppressive, a steroid, and an anti-TNF-α compound ~~or other classes of compounds indicated for the treatment of rheumatoid arthritis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, of Claim 61.

Claim 93 (withdrawn – currently amended): A method of treating rheumatoid arthritis which comprises co-administration of or use in combination with a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, an anti-TNF-α compound, and a PDE IV inhibitor ~~or other classes of compounds indicated for the treatment of rheumatoid arthritis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, as defined in Claim 67.

Claim 94 (withdrawn – currently amended): The method of Claim 92 wherein the COX-2 inhibitor is ~~Celebrex~~ celecoxib or ~~Vioxx~~ rofexoxib, the COX-1 inhibitor is ~~Feldene~~ piroxicam, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is ~~Enbrel~~ etanercept or ~~Remicade~~ infliximab.

Claim 95 (withdrawn – currently amended): The method of Claim 93 wherein the COX-2 inhibitor is ~~Celebrex~~ celecoxib or ~~Vioxx~~ rofexoxib, the COX-1 inhibitor is ~~Feldene~~ piroxicam, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is ~~Enbrel~~ etanercept or ~~Remicade~~ infliximab.

Claim 96 (withdrawn – currently amended): A composition for treating rheumatoid arthritis which comprises a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, and an anti-TNF-α compound ~~or other classes of compounds indicated for the treatment of rheumatoid arthritis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, as defined in Claim 61.

Claim 97 (withdrawn – currently amended): A composition for treating rheumatoid arthritis which comprises a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid, and an anti-TNF-α compound ~~or other classes of compounds indicated for the treatment of rheumatoid arthritis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, as defined in Claim 67.

Claim 98 (withdrawn – currently amended): The composition of Claim 96 wherein the COX-2 inhibitor is ~~Celebrex~~ celecoxib or ~~Vioxx~~ rofexoxib, the COX-1 inhibitor is ~~Feldene~~ piroxicam, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is ~~Enbrel~~ etanercept or ~~Remicade~~ infliximab.

Claim 99 (withdrawn – currently amended): The composition of Claim 97 wherein the COX-2 inhibitor is ~~Celebrex~~ celecoxib or ~~Vioxx~~ rofexoxib, the COX-1 inhibitor is ~~Feldene~~ piroxicam, the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is ~~Enbrel~~ etanercept or ~~Remicade~~ infliximab.

Claim 100 (withdrawn – currently amended): A method of treating multiple sclerosis which comprises co-administration of or use in combination with a compound selected from ~~Avonex~~ interferon beta-1a, ~~Betaseron~~ interferon beta-1b, and ~~Copaxone~~ glatiramer acetate ~~or other compounds indicated for the treatment of multiple sclerosis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, as defined in Claim 61.

Claim 101 (withdrawn – currently amended): A method of treating multiple sclerosis which comprises co-administration of or use in combination with a compound selected from ~~Avonex~~ interferon beta-1a, ~~Betaseron~~ interferon

beta-1b, and ~~Copaxone~~ glatiramer acetate ~~or other compounds indicated for the treatment of multiple sclerosis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, of Claim 67.

Claim 102 (withdrawn – currently amended): A composition for treating multiple sclerosis which comprises a compound selected from ~~Avonex~~ interferon beta-1a, ~~Betaseron~~ interferon beta-1b, and ~~Copaxone~~ glatiramer acetate ~~or other compounds indicated for the treatment of multiple sclerosis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, of Claim 61.

Claim 103 (withdrawn – currently amended): A composition for treating multiple sclerosis which comprises a compound selected from ~~Avonex~~ interferon beta-1a, ~~Betaseron~~ interferon beta-1b, and ~~Copaxone~~ glatiramer acetate ~~or other compounds indicated for the treatment of multiple sclerosis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, of Claim 67.

Claim 104 (withdrawn – currently amended): A method of treating psoriasis which comprises co-administration of or use in combination with a compound selected from the class consisting of an immunosuppressive, a steroid, and an anti-TNF-α compound ~~or other classes of compounds indicated for the treatment of psoriasis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, of Claim 61.

Claim 105 (withdrawn – currently amended): A method of treating psoriasis which comprises co-administration of or use in combination with a compound selected from the class consisting of an immunosuppressive, a steroid, and an anti-TNF-α compound ~~or other classes of compounds indicated for the treatment of psoriasis~~ and a compound, a prodrug thereof, or a

pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, as defined in Claim 67.

Claim 106 (withdrawn – currently amended): The method of Claim 104 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is ~~Enbrel~~ etanercept or ~~Remicade~~ infliximab.

Claim 107 (withdrawn – currently amended): The method of Claim 105 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is ~~Enbrel~~ etanercept or ~~Remicade~~ infliximab.

Claim 108 (withdrawn – currently amended): A composition for treating psoriasis which comprises a compound selected from the class consisting of an immunosuppressive, a steroid, and an anti-TNF-α compound ~~or other classes of compounds indicated for the treatment of psoriasis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, as defined in Claim 61.

Claim 109 (withdrawn – currently amended): A composition for treating psoriasis which comprises a compound selected from the class consisting of an immunosuppressive, a steroid, and an anti-TNF-α compound ~~or other classes of compounds indicated for the treatment of psoriasis~~ and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of ~~the~~ a compound or of said prodrug, as defined in Claim 67.

Claim 110 (withdrawn – currently amended): The composition of Claim 108 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is ~~Enbrel~~ etanercept or ~~Remicade~~ infliximab.

Claim 111 (withdrawn – currently amended): The composition of Claim 109 wherein the immunosuppressive is methotrexate, leflunimide, sulfasalazine

or cyclosporin, the steroid is β-methasone and the anti-TNF-α compound is ~~Enbrel~~ etanercept or ~~Remicade~~ infliximab.

Claim 112 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCH_3$ and R^1 is $-CH_3$.

Claim 113 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_2H$ and R^1 is $-CH_3$.

Claim 114 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CH_3 and R^1 is -CH_3.

Claim 115 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is -CH_3.

Claim 116 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CF_3$ and R^1 is $-CF_3$.

Claim 117 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-CF_3$.

Claim 118 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CF_3$ and R^1 is $-CH_3$.

Claim 119 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-N(CH_3)_2$.

Claim 120 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_3$ and R^1 is $-CH_3$.

Claim 121 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_3$ and R^1 is $-CF_3$.

Claim 122 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CH_3$ and R^1 is $-CF_3$.

Claim 123 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-CH_3$.

Claim 124 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-CF_3$.

Claim 125 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is $-CF_3$.

Claim 126 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CH_3.

Claim 127 (new): A method of treating asthma comprising co-administration of or use in combination with montelukast sodium, zafirlukast, or albuterol and a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of a compound or of said prodrug of Claim 61.

Claim 128 (new): A compound of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein:

R^1 is H, alkyl, haloC_1-C_6 alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, $N(R^2)_2$, or NR^2aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C_1-C_6 alkyl;

R^3 is H, C_1-C_6 alkyl, Cl, F, CF_3, OCF_2H, OCF_3, OH or C_1-C_6 alkoxy;

R^4 is H, C_1-C_6 alkyl, C_1-C_6 alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, $N(R^2)_2$, or NR^2aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;

R^5 is H or C_1-C_6 alkyl;

R^6 is H or C_1-C_6 alkyl; or

L^1 is -$S(O_2)$-, -S(O)-, or -S-;

L^2 is -$S(O_2)$-, -S(O)-, or -S-;

X is the same or different, and is independently selected from H, halogen, CF_3, CN, OCF_2H, OCF_2CF_3, OCF_3, OR^2, C_1-C_6 alkyl, cycloalkyl, cycloalkoxy, C_1-C_6 alkoxy, alkoxyC_1-C_6 alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, -OSO_2R^2, -$COOR^2$, -$CON(R^2)_2$, NHR^2, arylNH-, $N(R^2)_2$, or NR^2 aryl;

Y is a covalent bond, -CH_2-, -$S(O_2)$-, or  ;

Z is a covalent bond, -CH_2-, -$S(O_2)$- or  ; or

Y, R^1, Z and R^2 can be taken together with the nitrogen atom to form a heterocycloalkyl; with the proviso that if Y is a covalent bond, R^1 cannot form a N-N bond with the nitrogen atom; and

n is an integer of 0 to 4.

Claim 129 (new): A compound of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein:

R^1 is H, alkyl, haloC_1-C_6 alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, $N(R^2)_2$, or NR^2aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C_1-C_6 alkyl;

R^3 is H, C_1-C_6 alkyl, Cl, F, CF_3, OCF_2H, OCF_3, OH or C_1-C_6 alkoxy;

R^4 is H, C_1-C_6 alkyl, C_1-C_6 alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, $N(R^2)_2$, or NR^2aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;

R^5 is H or C_1-C_6 alkyl;

R^6 is H or C_1-C_6 alkyl;

R^5 and R^6 taken together with the carbon atom to form a carbonyl group;

L^1 is -$S(O_2)$-, -S(O)-, or -S-;

L^2 is -$S(O_2)$-, -S(O)-, or -S-;

X is the same or different, and is independently selected from H, halogen, CF_3, CN, OCF_2H, OCF_2CF_3, OCF_3, OR^2, C_1-C_6 alkyl, cycloalkyl, cycloalkoxy, C_1-C_6 alkoxy, alkoxyC_1-C_6 alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, -OSO_2R^2, -$COOR^2$, -$CON(R^2)_2$, NHR^2, arylNH-, $N(R^2)_2$, or NR^2 aryl;

Y is a covalent bond, -CH_2-, -$S(O_2)$-, or  ; and

n is an integer of 0 to 4.